Preventing Early Renal Function Loss in Diabetes (PERL)

Preventing Early Renal Loss in Diabetes Logo

What is PERL?

PERL stands for Preventing Early Renal Function Loss in Diabetes. The PERL study is a three-year multi-center study aiming to determine whether allopurinol can reduce loss of renal function in people with type 1 diabetes. Patients with type 1 diabetes remain at risk for end-stage renal disease despite improvements in blood pressure and blood glucose control. Allopurinol is a medication that has been on the market for almost 50 years, has an excellent safety profile, and is used to prevent gout in patients with elevated uric acid levels. There is evidence suggesting that allopurinol might also be useful in people with diabetes who have normal or moderately impaired kidney function to decrease the risk of developing advanced kidney disease in the future.

Eligibility to participate

You may be eligible to participate in the PERL study if you:

  • Are between the ages of 18 – 70 years
  • Have type 1 diabetes for at least 8 years
  • Are concerned you may have or may develop kidney problems related to diabetes

This study does not accept healthy participants.
This study is currently recruiting participants.

What is involved in the Study?

  • Participants will be randomly selected to take allopurinol or a placebo (inactive pill) for three years.
  • During this time, participants will periodically have follow up visits at the University of Minnesota.
  • Kidney function will be measured at the beginning and at the end of the treatment period

Principal Investigator

Luiza Caramori, MD, PhD


For More Information

perl-t1d@umn.edu
(800) 688-5252 (Ext. # 1-2103)

Sara Eischen
(612) 301-2103

Florence John
(612) 301-6685